Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Dow
Colorcon
Chinese Patent Office
Baxter
Johnson and Johnson
Queensland Health
Citi

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021106

« Back to Dashboard

NDA 021106 describes SOMAVERT, which is a drug marketed by Pharmacia And Upjohn and is included in one NDA. It is available from one supplier. Additional details are available on the SOMAVERT profile page.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.
Summary for 021106
Tradename:SOMAVERT
Applicant:Pharmacia And Upjohn
Ingredient:pegvisomant
Patents:0
Suppliers and Packaging for NDA: 021106
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106 NDA Pharmacia and Upjohn Company LLC 0009-5176 0009-5176-01 1 KIT in 1 PACKAGE (0009-5176-01) * 1 mL in 1 VIAL, SINGLE-DOSE (0009-5175-01) * 1 mL in 1 VIAL, SINGLE-DOSE
SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106 NDA Pharmacia and Upjohn Company LLC 0009-5176 0009-5176-02 1 KIT in 1 PACKAGE (0009-5176-02) * 1 mL in 1 VIAL, SINGLE-DOSE (0009-5175-01) * 1 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength10MG/VIAL
Approval Date:Mar 25, 2003TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength15MG/VIAL
Approval Date:Mar 25, 2003TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength20MG/VIAL
Approval Date:Mar 25, 2003TE:RLD:Yes

Expired US Patents for NDA 021106

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-004 Jul 31, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
Cipla
Julphar
Medtronic
Deloitte
Chubb
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.